Skip to content

Annals of Clinical and Analytical Medicine

E-ISSN: 2667-663X · Monthly · English

The effect of body composition on prognosis in critically ill covid-19 patients

Sarcopenia in ICU patients diagnosed with covid-19

Abstract

AimAlthough limited risk factors were observed with the accumulated evidence during the SARS-CoV-2 (COVID-19) pandemic, there is still a lack of evidence for markers distinguishing asymptomatic-mild disease from severe disease. In this study, we aimed to evaluate the prognostic impact of sarcopenia and vis- ceral adipose tissue in ICU patients treated for COVID-19.MethodsThe study designed as a retrospective cross-sectional study for evaluating the effect of prognostic radiologic features in COVID-19 infected patients. The patient characteristics, intubation status and dates, transfer to ICU, and last control or death dates were recorded. Axial CT images, including all abdominal muscles, total skeletal muscle area, were calculated. The total and psoas sarcopenia index (PSI) was calculated by dividing the square of the patient’s height by the square meter (cm2/m2). Also, axial CT images of the body fat subcutaneous adipose and visceral adipose tissue distribution areas were calculated in cm2 using threshold values of -30 to -190 for adipose tissue.ResultsIn the study population, there were nine deaths that occurred among male patients. In univariate analysis, chronic obstructive pulmonary disease and PSI were found to be related to prognosis. The median survival was 14 days in PSI low group. The prognostic effect of the PSI was still valid in the male population. Other factors had no relationship with survival in univariate analysis. In multivariate analysis, the prognostic effect of TSI and PSI was related to prognosis, while COPD lost its prognostic effect.ConclusionIn this study, we found a new prognostic factor in critically ill COVID-19 patients, which may be a new area of interest. In contrast to other studies, we found no effect of BMI and visceral adipose tissue on mortality in COVID-19 patients treated in ICU. This feasible method needs further evaluation and validation with prospective studies in a large patient population.

Keywords

covid-19mortalitysarcopeniavisceral adipose tissueprognosiscritically ill patients

Introduction

SARS-CoV-2 (COVID-19) is a single-stranded RNA spherical virus which has glycoprotein spikes.1 Multiple subtypes of coronaviruses have the capability of infecting humans. The major subgroups which have severe infection capacity are COVID-19, MERS, and SARS-CoV-1.2 The primary target of the COVID-19 is angiotensin-converting enzyme-2 (ACE-2) located on the alveolus and ciliated bronchial epithelium. Air- borne droplets were shown to be the direct dissemination way of the viral particles.3 Cough, fever, and shortness of breath are the most frequent symptoms of the disease. It has been reported that myocardial damage, respiratory and renal failure are the leading reasons for death in COVID-19 patients.4 Approximately 200.000 deaths, confirmed by the World Health Organization, occurred related to COVID-19 till April 25, 2020 worldwide.5
According to the literature, the groups most affected by COVID-19 were immunocompromised and older adults. High rates of respiratory failure during the disease are the major problem in COVID-19 infection.6 Although limited risk factors with the accumulated evidence were observed during the pandemic, there is still a lack of evidence for markers distinguishing asymptomatic-mild disease from severe disease.7
Catabolism of the main skeletal muscle proteins is a frequent phenomenon for chronic conditions such as cancer and chronic obstructive lung disease.8 Also, cachexia is known to be related to increased mortality in cancer patients.9 Differences in body composition between males and females have been observed in previous studies in both healthy subjects, patients with cirrhosis, or cancer. Muscle tissue was enlarged in males, while females had enlarged adipose tissue.10 Sarcopenia is one of the new areas of interest in cancer patients in relation to a clinical marker.11 Obesity, according to body mass index (BMI), is associated with a decreased treatment response in breast cancer patients.12 Obese patients are not uniform; some patients remain metabolically stable, which is called the ‘obesity paradox’.13 In addition, sarcopenia can be masked by increased BMI, which leads to the phenomenon of sarcopenic obesity.14 For these reasons, BMI is not a reliable marker for estimating body composition and disease prognosis.
A new study reported that increased BMI might be related to increased mortality in patients hospitalized for COVID-19.15 Computed tomography (CT) is a reliable method to evaluate the muscle quality and adipose tissue.16
To our knowledge, there are no studies investigating the prognostic effect of sarcopenia in critically ill patients hospitalized for COVID-19. In this study, we try to evaluate the prognostic impact of sarcopenia and visceral adipose tissue in ICU patients treated for COVID-19.

Materials and Methods

Study ParticipantsThe archive records of patients, who were diagnosed with COVID-19 between 11th March 2020 and 15th June 2020 at the Eskişehir City Hospital Intensive Care Unit, were retrospectively analyzed. Patients with COVID-19 were diagnosed using PCR. Oropharyngeal and nasal swabs were obtained in PCR samples.
Patients who do not have PCR testing or have inadequate diagnosis were excluded. Patient characteristics, height, weight, comorbidities such as diabetes mellitus (DM), hypertension (HT), chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD), smoking status, diagnosis, intubation status and dates, transfer to ICU, and last control or death dates were recorded. The exclusion criteria were lack of adequate diagnosis, CT images, and follow-up.EthicsThe study was approved by the Turkish Ministry of Health and the Ethics Committee of the Faculty of Medicine at Eskişehir Osmangazi University (approval number 2020/277) and was carried out in accordance with the Declaration of Helsinki principles and all applicable regulations.Statistical AnalysisStatistical analysis of the study was performed using SPSS software (Statistical Package for the Social Sciences, version 22.0, SPSS Inc, Chicago, IL). Descriptive data were presented as either means or median for continuous variables, frequencies and percentages were reported for categorical variables. ROC analysis was performed to determine the optimal cut-off value, but if an optimal cut-off value cannot be determined, the median values will be used in the statistical analysis. Pearson’s X2 test was used to assess the associations in categorical variables. OS curves were estimated by the Kaplan-Meier product- limit method. Life tables were established to determine the proportional survival analysis.Body Composition Assessment and CT AnalysisThe first CT images obtained in the emergency room or in the patient’s clinic were used in the study to avoid calculating COVID-19 induced sarcopenia. On axial CT images, including all abdominal muscles (psoas, erector spinae, quadratus lumborum, external and internal oblique, and rectus abdominis), total skeletal muscle area (SMA) was calculated from the third lumbar vertebrate (Figure 1). The total and psoas sarcopenia index (TSI-PSI) was calculated by dividing the square of the patient’s height by the square meter (cm2/m2). Also, axial CT images of the body fat subcutaneous adipose and visceral adipose tissue distribution (VAT, SAT) areas were calculated in cm2 using threshold values of -30 to -190 for adipose tissue (Figure 2).

Results

Thirty-six patients were included in the study. Four patients were excluded due to a lack of adequate imaging procedures. The counts of male and female patients in the study were 28 and 8, respectively. The median age of the study population was 68 years. The median weight, height, and BMI of the study population were 80 kilograms, 1.7 meters, and 26,8 kg/m2, respectively. The demographic features of the study population are described in Table 1.
In the study population, there were nine deaths that occurred among male patients. No death was observed in female patients. In univariate analysis, COPD and PSI were found to be related to prognosis (P < .001,001, P < .001,010). Although median survival was not reached in the high PSI group, PSI had a relationship with prognosis (Figure 3). The median survival was 14 days in the low PSI group. The prognostic effect of the PSI was still valid in the male population. (P < .001,007) Gender, DM, HT, CAD, TSI, VAT, BMI (categorized for both 25 and 30 kg/m2) had no relationship with survival in univariate analysis (Table 2). In multivariate analysis, the prognostic effect of TSI and PSI was related to prognosis, while COPD lost its prognostic effect (P < .001,044; P < .001,035; P < .001,33).

Discussion

To our knowledge, this is the first study that evaluates the prognostic effect of sarcopenia in ICU patients. In our research, TSI and PSI were found to be an independent risk factor in COVID-19 infected ICU patients.
COVID-19 is known to have high mortality in the geriatric population. Conditions such as sarcopenia and frailty are frequently seen in the elderly.17 Sarcopenia is defined as the loss of a prominent muscle tissue that is related to increased vulnerability to stressors.18 Previous studies have shown a relationship between sarcopenia and ICU mortality.19 Interestingly, COVID-19 infection was found to induce weight loss in animal models via interferon-gamma and tumor necrosis factor-alpha. This effect disappeared after the treatment.20 Regulations, including social isolation during the pandemic, were strictly applied, especially to the elder population, which may accelerate muscle loss in a short period. Also, chronic conditions such as DM and COPD are responsible for sarcopenia in this group.21 Although some new reports have been published, which have shown a relationship between high BMI and poor outcome in COVID-19 infection, no literature is available investigating sarcopenia in this condition. The death rates were higher in countries with a high prevalence of obesity, such as the United States of America (USA), Canada, the United Kingdom, and Mexico. This phenomenon was speculated to be related to sarcopenia, DM, CAD, increased function of the renin-angiotensin-aldosterone system (RAAS), obstructive sleep apnea, and deficiency of vitamin D. In the USA, a single- center experience showed that obesity and male gender are independent risk factors for COVID-19 infection.15 In addition, a study investigating patient outcomes in China reported more symptoms and a severe disease course with increasing BMI.23 In contrast to this literature, we did not found a significant relationship between BMI and COVID-19 infection, which might be related with sarcopenic obesity phenomenon. This result was supported by increased BMI but low mortality in female patients in the study population. Also, increased visceral adipose tissue was speculated to be a reservoir to the virus, which might induce an abnormal cytokine release and cause a poor outcome.24 In our study, we found no relationship between visceral adipose tissue and increased mortality in critically ill patients. Although obstructive sleep apnea might be related to increased mortality due to obesity, no data were available in our study.25

Limitations

The limitations of this study were the small sample size, and the retrospective nature of the study made it hard to evaluate the outcomes. Although the first images were used to assess sarcopenia on CT images, the early period of the disease might affect the body composition. No deaths were observed in female patients, which might inflict the strong prognostic effect of sarcopenia in this patient group.

Conclusion

In this study, we found a new prognostic factor in critically ill COVID-19 patients, which may be a new area of interest. In contrast to other studies, we found no effect of BMI and visceral adipose tissue on mortality in COVID-19 patients treated in ICU. This comfortable and applicable method needs further evaluation and validation with prospective studies in a large patient population.

Declarations

Animal and Human Rights Statement

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No animal or human studies were carried out by the authors for this article.

Data Availability

The datasets used and/or analyzed during the current study are not publicly available due to patient privacy reasons but are available from the corresponding author on reasonable request.

Conflict of Interest

None of the authors received any type of financial support that could be considered potential conflict of interest regarding the manuscript or its submission.

Funding

None.

References

  1. Wassenaar TM, Zou Y. 2019_nCoV/SARS-CoV-2: rapid classification of betacoronaviruses and identification of Traditional Chinese Medicine as potential origin of zoonotic coronaviruses. Lett Appl Microbiol. 2020;70(5):342-348. doi:10.1111/lam.13285
  2. Gorbalenya A, Baker S, Baric R, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus Study Group. Nat Microbiol. 2020. doi:10.1101/2020.02.07.937862
  3. Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus epidemic: evidence for virus evolution. J Med Virol. 2020;92:455-459. doi:10.1002/jmv.25688
  4. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35(5):1545-1549. doi:10.1007/s11606-020-05762-w
  5. Livingston E, Bucher K, Rekito A. Coronavirus disease 2019 and influenza 2019-2020. JAMA. 2020;323(12):1122. doi:10.1001/jama.2020.2633
  6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016/s0140-6736(20)30211-7
  7. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. doi:10.1016/j.jaci.2020.04.006
  8. van de Bool C, Gosker HR, van den Borst B, Op den Kamp CM, Slot IGM, Schols AMWJ. Muscle quality is more impaired in sarcopenic patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2016;17:415-420. doi:10.1016/j.jamda.2015.12.094
  9. Johns N, Stephens NA, Fearon KCH. Muscle wasting in cancer. Int J Biochem Cell Biol. 2013;45(10):2215-2229. doi:10.1016/j.biocel.2013.05.032
  10. Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care. 2001;4(6):499-502. doi:10.1097/00075197-200111000-00006
  11. Ligibel JA, Wollins D. American Society of Clinical Oncology obesity initiative: rationale, progress, and future directions. J Clin Oncol. 2016;34(35):4256-4260. doi:10.1200/jco.2016.67.4051
  12. Fontanella C, Lederer B, Gade S, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat. 2015;150(1):127-139. doi:10.1007/s10549-015-3287-5
  13. Denis GV, Obin MS. “Metabolically healthy obesity”: origins and implications. Mol Aspects Med. 2013;34(1):59-70. doi:10.1016/j.mam.2012.10.004
  14. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629-635. doi:10.1016/s1470-2045(08)70153-0
  15. Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262. doi:10.1016/j.metabol.2020.154262
  16. Shen W, Punyanitya M, Wang ZM, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97(6):2333-2338. doi:10.1152/japplphysiol.00744.2004
  17. Koff WC, Williams MA. COVID-19 and immunity in aging populations—a new research agenda. N Engl J Med. 2020;383(9):804-805. doi:10.1056/nejmp2006761
  18. Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two sides of the same coin. Front Aging Neurosci. 2014;6:192. doi:10.3389/fnagi.2014.00192
  19. Toptas M, Yalcin M, Akkoc E, et al. The relation between sarcopenia and mortality in patients at intensive care unit. Biomed Res Int. 2018;2018:5263208. doi:10.1155/2018/5263208
  20. Chan JFW, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020.
  21. Dent E, Morley JE, Cruz-Jentoft AJ, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging. 2018. doi:10.1007/s12603-018-1139-9
  22. Zores F, Rebeaud ME. COVID and the renin-angiotensin system: are hypertension or its treatments deleterious? Front Cardiovasc Med. 2020. doi:10.3389/fcvm.2020.00071
  23. Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020. doi:10.2337/dci20-0034
  24. Ryan PMD, Caplice NM. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity (Silver Spring). 2020. doi:10.1002/oby.22843
  25. Pazarlı AC, Ekiz T, İlik F. Coronavirus disease 2019 and obstructive sleep apnea syndrome. Sleep Breath. 2020.

Tables

Table 1. The comparative features of the study population according by gender

BMI: Body Mass Index, DM: Diabetes Mellitus, HT: Hypertension, COPD: Chronic Obstructive Pulmonary Disease, CT: Computed Tomography.

Table 2. Univariate analysis of the features of the study population

DM: Diabetes Mellitus, HT: Hypertension, CAD: Coronary Artery Disease, COPD: Chronic Obstructive Pulmonary Disease, PSI: Psoas Sarcopenia Index, TSI: Total Sarcopenia Index, VAT: Visceral Adipose Tissue, BMI: Body Mass Index, NR: Not Reached.

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

About This Article

How to Cite This Article

İsmail Beypınar, Murat Bayav, Anıl Uçan, Serdar Efe. The effect of body composition on prognosis in critically ill covid-19 patients. Ann Clin Anal Med 2021;12(6):680-684. doi:10.4328/ACAM.20383

Publication History

Received:
25.10.2020
Accepted:
24.11.2020
Published Online:
05.12.2020
Printed:
01.06.2021